Related Experiment Video
Updated: May 6, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells
Sung Su Kim1, Sin Seong, Seong Hyeon Lim
1M.D., School of Medicine, Konkuk University, Seoul 143-701, Republic of Korea. palelamp@kku.ac.kr.
Background/Aim:
Altered redox status has been reported to play a significant role in the development of multidrug resistance (MDR) in leukemia cells. Human biliverdin reductase (hBVR) has been recently identified as a major cytoprotectant; however, its role in MDR has not been yet investigated. In the present study we evaluated the possible role of hBVR in MDR development in the human HL60 leukemia cell line.
Materials And Methods:
The relationship between hBVR and MDR was examined using the drug-sensitive HL60 cells and the drug-resistant HL60 subline, HL60/ADR. A possible chemosensitization by siRNA pre-treatment was also investigated.
Results:
We observed that hBVR expression, protein, and enzymatic activity were significantly increased in multidrug-resistant HL60 leukemia cells. We also found that knockdown of hBVR reverses multidrug resistance in resistant leukemic HL60 cells by a ROS-dependent mechanism.
Conclusion:
hBVR plays a pivotal role in the development of multidrug resistance in human HL60 leukemia cells.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase